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Abstract: Although renal transplantation ameliorates cardiovascular risk factors by restoring 
renal function, it introduces new cardiovascular risks including impaired glucose tolerance or 
diabetes mellitus, hypertension, and dyslipidemia that are derived, in part, from immunosup-
pressive medications such as calcineurin inhibitors, corticosteroids, or mammalian target of 
rapamycin inhibitors. New onset diabetes mellitus after transplantation (NODAT) is a serious 
and common complication following solid organ transplantation. NODAT has been reported 
to occur in 2% to 53% of all solid organ transplants. Kidney transplant recipients who develop 
NODAT have variably been reported to be at increased risk of fatal and nonfatal cardiovascular 
events and other adverse outcomes including infection, reduced patient survival, graft rejection, 
and accelerated graft loss compared with those who do not develop diabetes. Identification 
of high-risk patients and implementation of measures to reduce the development of NODAT 
may improve long-term patient and graft outcome. The following article presents an overview 
of the literature on the current diagnostic criteria for NODAT, its incidence after solid organ 
transplantation, suggested risk factors and potential pathogenic mechanisms. The impact of 
NODAT on patient and allograft outcomes and suggested guidelines for early identification 
and management of NODAT will also be discussed.
Keywords: new onset diabetes after transplantation (NODAT), cyclosporine, tacrolimus, 
sirolimus, hepatitis C and diabetes, cytomegalovirus and diabetes
Definition and diagnosis of new onset diabetes  
after transplantation
Over the years, the precise incidence of new onset diabetes after transplantation 
(NODAT) has been difficult to determine due to the lack of a standard definition for 
the condition. Historically, post-transplant diabetes has been variably defined as having 
random glucose levels greater than 200 mg/dL or fasting glucose levels greater than 
140 mg/dL, or the need for insulin or oral hypoglycemic agents in the post-transplant 
period. In 2003, the International Expert Panel consisting of experts from both the 
transplant and diabetes fields set forth the International Consensus Guidelines for 
the diagnosis and management of NODAT.1,2 It was recommended that the defini-
tion and diagnosis of NODAT should be based on the definition of diabetes mellitus 
and impaired glucose tolerance (IGT) described by the World Health Organization 
(WHO).2,3 The current WHO and American Diabetes Association (ADA) guidelines 
for the diagnosis of prediabetic states (impaired fasting glucose (IFG) and IGT) and 
diabetes mellitus are provided in Table 1.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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Incidence
New onset diabetes mellitus after transplantation has been 
reported to occur in 4% to 25% of renal transplant recipients, 
2.5% to 25% of liver transplant recipients, 4% to 40% of 
heart transplant recipients, and 30% to 35% of lung trans-
plant recipients.1,4–6 The variation in the reported incidence 
may be due in part to the lack of a standard definition of the 
condition, the duration of follow-up, the presence of both 
modifiable and non-modifiable risks factors, and the type of 
organ transplants. In hepatitis C virus (HCV)-infected liver 
recipients, the prevalence of NODAT has been reported to 
range between 40% to 60%.4,5,7 Similar to the nontransplant 
settings, the use of fasting plasma glucose (FPG) versus oral 
glucose tolerance test (OGTT) to define diabetes mellitus also 
changes the prevalence of NODAT. In a prospective study 
designed to evaluate the use of OGTT for risk-stratifying 
patients for NODAT, Sharif et al8 demonstrated that among 
122 renal transplant recipients without diabetes who had two 
fasting plasma glucose (FPG) level measurements within 
the range of 100–125 mg/dL (5.6–6.9 mmol/L) for more 
than 6 months after transplantation, OGTTs revealed that 
10% had overt diabetes mellitus, 9% had IGT alone, 18% 
had IFG alone (all defined by WHO criteria), and 14% had 
combined IFG and IGT.
Risk factors for NODAT
Risk factors for the development of NODAT are categorized 
as non-modifiable, modifiable or potentially modifiable, the 
former category to facilitate the identification of high risk 
individuals, and the latter two categories to optimize the 
management of NODAT. Suggested risk factors for NODAT 
are summarized in Figure 1.
Nonmodifiable risk factors
Age
Older age has long been observed to be an important risk 
factor for the development of NODAT. Cosio et al9 dem-
onstrated that transplant recipients older than 45 years of 
age were 2.2 times more likely to develop NODAT than 
those younger at the time of transplantation (P , 0.0001). 
  Similarly, in an analysis of the US Renal Data System 
(USRDS) consisting of over 11,000 Medicare beneficiaries 
who received primary kidney transplants between 1996 and 
2000, Kasiske et al10 showed a strong association between 
older age and NODAT. Compared to a reference range 
of 18–44 years of age, transplant recipients between the 
age of 45–59 years had a relative risk for NODAT of 1.9 
(P , 0.0001), whereas those who were $60 years of age 
had a relative risk of 2.09 (P , 0.0001).9
Race/ethnicity
There has been ample literature suggesting that African 
Americans and Hispanics are at increased risk for developing 
Non-modifiable Potentially modifiable Modifiable
•A frican American, Hispanic
•A ge > 40–45 yrs
• Recipient male gender
• Family history of DM
• HLA A30, B27, B42
• HLA mismatches
•A cute rejection history
• Deceased donor 
• Male donor
•P olycystic kidneys 
Individualization of 
Immunosuppressive therapy
•T acrolimus
•C yclosporine
•C orticosteroid
• mTOR inhibitors
• Anti CD25 mAB?b
Obesity or other component 
of the metabolic syndrome
•H CV
•C MV
• Pre-tx IFG/IGT
• Proteinuria?a
• HypoMg?a
Figure 1 Risk factors for NODAT.
Abbreviations:  Anti  CD25  mAb?b,  Anti  CD25  monoclonal  antibody;  CMv, 
cytomegalovirus; HCv, hepatitis C; HypoMg, hypomagnesemia; Pre-Tx, pre-transplant. 
Notes:  Restoration  of  insulin  metabolism  by  a  functioning  graft  may  unmask 
pre-transplant impaired glucose tolerance or diabetes and is not a risk factor per se. 
aSee text. bFurther studies are needed
Table 1 wHO and 2003 updated ADA criteria for the diagnosis 
of diabetes mellitus
Criteria for the diagnosis of diabetes mellitus
 •    Symptomsa of diabetes mellitus + casualb PG concentrations 
$200 mg/dL (11.1 mM)
  or
  •   FPG $ 126 mg/dL (7.0 mM). Fasting is defined as no caloric intake 
for at least 8 hours
  or
 •  2-hr PG $ 200 mg/dL (11.1 mM) during an oral glucose tolerance testc
A confirmatory laboratory test based on measurements of venous PG must 
be done on another day in the absence of unequivocal hyperglycemia 
accompanied by acute metabolic decompensation.
Criteria for normal FPG and IFG or IGT
FPG
  WHO criteria
  FPG , 110 mg/dL (6.1 mM) = normal fasting glucose
  FPG $ 110 mg/dL (6.1 mM) and ,126 mg/dL (7.0 mM) = iFG
  2003 ADA updated consensus report
  FPG , 100 mg/dL (5.6 mM) = normal fasting glucose
  FPG $ 100 mg/dL (5.6 mM) and ,126 mg/dL (7.0 mM) = iFG
or
OGTT
  2-hr PG , 140 mg/dL (7.8 mM) = normal glucose tolerance
  2-hr PG $ 140 mg/dL (7.8 mM) and ,200 mg/dL (11.1 nM) = iGT
Notes: aClassic symptoms of diabetes include polyuria, polydipsia, and unexplained 
weight loss; bCasual is defined as any time of day without regard to time since last 
meal; cOGTT: the test should be performed as described by wHO, using a glucose 
load containing equivalent of 75 g anhydrous glucose dissolved in water.
Copyright  ©  2003,  wolters  Kluwer  Health.  Reproduced  with  permission  from 
Davidson et al.1
Abbreviations:  wHO,  world  Health  Organization;  PG,  plasma  glucose;  FPG, 
fasting plasma glucose; iFG, impaired fasting glucose; iGT, impaired glucose tolerance; 
OGTT, oral glucose tolerance test.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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NODAT compared to whites. In a single-center retrospective 
study consisting of 122 renal transplant recipients, the risk 
of developing NODAT as defined by the 2003 International 
guidelines was double in African Americans compared to 
whites.11 Similarly, data from the USRDS demonstrated 
that NODAT was more common among African   Americans 
(RR = 1.68, P , 0.0001) and Hispanics (RR = 1.35, 
P , 0.0001) compared with Caucasians. The difference 
in the incidence of NODAT in patients of different ethnic-
ity has been suggested to be due in part to the differential 
pharmacokinetics and diabetogenic effects of immunosup-
pressive agents.3 Tacrolimus has also been reported to have 
particularly potent diabetogenic effects in African Americans 
compared with whites.1 It is also possible that cultural dif-
ferences in lifestyle may be contributory.
Family history of diabetes mellitus
Similar to type 2 diabetes in the general population, both 
genetic and environmental factors have been suggested to 
play a role in the development of NODAT. There is strong 
evidence suggesting that individuals with a family history of 
diabetes among first-degree relatives have an increased risk 
of developing NODAT, with one study reporting a seven-
fold increase in the condition.1 The increased prevalence of 
NODAT associated with a family history of diabetes has been 
documented across all types of solid organ transplantation. 
In a Spanish multicenter cross-sectional study consisting of 
1410 recipients of kidney transplants, 489 liver transplants, 
207 heart transplants, and 72 lung transplants, a positive fam-
ily history of diabetes was associated with a 50% increase in 
the risk of developing NODAT (odds ratio of 1.51).12
Other non-modifiable risk factors include recipient male 
gender; the presence of certain human leukocyte antigens 
(HLA) such as HLA A30, B27, and B42; increasing HLA 
mismatches; donor-recipient (DR) mismatch; deceased donor 
kidneys; male donor; and acute rejection history.13 Polycystic 
kidney disease has been suggested to confer an increased risk 
of developing diabetes after renal transplantation in some 
studies but not in others.14–17
Modifiable risk factors
Corticosteroid-associated NODAT
The now well-established contributory role of corticoster-
oids on NODAT was first described by Starlz in 1964 in 
renal transplant recipients.9,18 The diabetogenic effect of 
corticosteroids has been suggested to be dose-dependent. 
  Single-center studies have demonstrated that oral predni-
solone dose reduction to 5 mg daily significantly improves 
glucose tolerance during the first year after transplantation19 
while a 0.01 mg/kg/day increase in prednisolone dose is 
associated with a 5% risk of developing NODAT.20
In a small study involving 57 stable renal transplant 
recipients, Midtvedt and colleagues21 found that prednisolone 
dose reduction from a mean of 16 mg daily (range 10 to 30) 
to 9 mg daily (range 5 to 12.5) resulted in an average increase 
in insulin sensitivity index of 24%. However, complete with-
drawal of 5 mg/day of prednisolone did not influence insulin 
sensitivity significantly. Whether complete withdrawal of 
chronic low dose corticosteroid therapy (prednisolone 5 mg 
daily) improves glucose metabolism remains to be studied. 
Nonetheless, in recent years several studies have suggested a 
potential beneficial effect of steroid-free immunosuppression 
on NODAT risk reduction.22
In a retrospective analysis of the Organ Procurement 
Transplant Network/Scientific Registry of Transplant 
  Recipient (OPTN/SRTR) database consisting of .25,000 
kidney transplant recipients engrafted between January 2004 
and December 2006, Luan et al22 demonstrated that steroid-
free immunosuppression was associated with a significant 
reduction in the likelihood of developing NODAT compared 
with steroid-containing regimens. The cumulative incidence 
of NODAT within three years post-transplant were 12.3% 
in steroid-free versus 17.7% in steroid-containing regimens, 
P , 0.001. Overall, steroid-containing regimens at the time 
of hospital discharge were associated with a 42% increased 
risk for NODAT. Notably, patients from programs that fre-
quently adopted steroid-free regimens had reduced odds of 
NODAT compared with those from programs that commonly 
used steroid-containing regimens.
The dose dependent diabetogenic effect of corticos-
teroids was also observed in recipients of nonrenal organ 
transplants. In a retrospective review involving 88 heart 
transplant recipients, Depcynski and colleagues23 found that 
patients who developed NODAT had received higher mean 
doses of prednisolone at 3 months compared with those who 
remained free of diabetes at a mean follow-up of 27 months 
(0.21 ± 0.03 versus 0.19 ± 0.03 mg/kg/day, P , 0.01).
Calcineurin inhibitor(CNi)-associated  
NODAT: cyclosporine versus tacrolimus
Although clinical trials comparing the incidence of NODAT 
in cyclosporine A (CSA)- versus tacrolimus (Tac)-treated 
patients have yielded mixed results, Tac has more   consistently 
been shown to have a greater diabetogenic effect.24,25
The DIRECT Study (Diabetes Incidence after Renal 
Transplantation: Neoral C2 monitoring versus Tacrolimus) Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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was the first multi-center open label, randomized trial to assess 
  glucose abnormalities in de novo kidney transplant patients 
who were randomized to cyclosporine microemulsion- 
(CSA-ME) or tacrolimus-based immunosuppression.26 
The incidence of NODAT or IFG (defined by WHO/ADA 
criteria) at 6-month post-transplant was significantly lower 
in CSA-ME- versus tacrolimus- treated patients, (26% 
versus 33.6%, P = 0.046). Furthermore, a lower proportion 
of CSA-ME patients with NODAT required hypoglycemic 
medication or dual therapy with insulin and oral hypo-
glycemic agents compared with their tacrolimus-treated 
counterparts.
The greater diabetogenic effect of tacrolimus compared 
to CSA has been reported to occur across renal and nonrenal 
transplant groups. In a meta-analysis to evaluate the reported 
incidence of NODAT after solid organ transplantation, 
Heisel and colleagues27 found a higher incidence of insulin-
dependent diabetes mellitus (IDDM) in Tac- versus CSA-
treated liver, heart, and lung transplant recipients. In renal 
transplant recipients, IDDM occurred in 9.8% of Tac-treated 
versus. 2.7% of CSA-treated patients (P , 0.00001). Similar 
trends were observed among recipients of non renal organ 
transplants (11.1% versus 6.2%, respectively (P , 0.003). 
Nonetheless, not all studies showed that Tac is more diabe-
togenic than cyclosporine.28 It has been suggested that these 
study inconsistencies partially stemmed from the difference 
in the definitions of NODAT and the difference in calcineurin 
inhibitor dose and drug levels.28,29 In a single-center study 
consisting of 139 renal transplant recipients without known 
pretransplant glucose abnormalities, Maes and colleagues29 
have shown that high Tac trough levels, particularly levels 
greater than 15 ng/mL in the first month after transplant, were 
a significant risk factor for persistent impaired fasting glucose 
or diabetes mellitus beyond the first year after   transplantation. 
In a single-center study consisting of 45 orthotopic liver 
transplant (OLT) recipients treated with either CSA (n = 9) 
or high- (n = 15) versus. low- (n = 13) dose Tac, the incidence 
of NODAT was 11%, 40% and 23%, respectively.30
interaction between tacrolimus and concomitant  
hepatitis C infection (HCv)
In a retrospective study of more than 400 kidney transplant 
recipients with no known pre-transplant diabetes, Bloom and 
colleagues31 have shown that among the HCV-positive cohort, 
NODAT occurred more often in the Tac- compared with 
the CSA-treated groups (57.8% versus 7.7%, P , 0.0001). 
In contrast, among the HCV-negative cohort, the rates of 
NODAT were similar between the two calcineurin inhibitor 
(CNI) groups (Tac versus CSA: 10% vs 9.4%, respectively, 
P = 0.521). Whether concomitant exposure to tacrolimus and 
HCV plays a synergistic role in the development of NODAT 
remains speculative.
effects of sirolimus (Sir) on glucose metabolism
Early large randomized clinical trials suggested that sirolimus 
is devoid of diabetogenic effects either used alone or in com-
bination therapy with CNI. However, the diabetogenicity of 
sirolimus has now been well-described. Teutenico et al32 dem-
onstrated that calcineurin inhibitors to sirolimus   conversion 
therapy and tacrolimus withdrawal in a regimen consisting 
of tacrolimus and sirolimus were associated with a 30% 
increased incidence of impaired glucose tolerance. In one 
single-center study, tacrolimus and sirolimus combination 
therapy was found to be associated with a higher incidence 
of NODAT than tacrolimus immunosuppression alone.11 
Subsequent large registry studies also demonstrated an asso-
ciation between sirolimus and the development of NODAT. 
In an analysis of the USRDS database consisting of more 
than 20,000 primary kidney transplant recipients receiving 
sirolimus or CNI (CsA or Tac) or both in various combina-
tion therapies with an antimetabolite [mycophenolate mofetil 
(MMF) or azathioprine (AZA)], Johnston et al33 demonstrated 
that patients treated with sirolimus in combination with a 
CNI (CsA or Tac) had the highest incidence of NODAT. The 
authors further demonstrated that patients treated with (Sir 
+ Tac) combination therapy had a hazard ratio of develop-
ing NODAT of 1.9 compared with those receiving (Tac + 
MMF/AZA), suggesting that sirolimus was associated with 
an increased risk for NODAT independent of any effect of 
tacrolimus.
effects of antimetabolites on NODAT
The antimetabolites AZA and MMF have not been shown 
to be diabetogenic. On the contrary, the concomitant use of 
MMF has been suggested to mitigate the diabetogenic effect 
of tacrolimus.10 It is conceivable that the use of azathioprine 
or MMF allows clinicians to use lower doses of other diabe-
togenic immunosuppressive medications.
Potential pathogenic mechanisms of CNi  
and mammalian target of rapamycin (mTOR)  
inhibitor-induced NODAT
An extensive discussion of the pathogenic mechanisms of 
immunosuppressive drug-induced NODAT is beyond the 
scope of the current manuscript. A summary of suggested 
mechanisms is shown in Table 2.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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retrospective analysis consisting of 640 nondiabetic renal 
transplant recipients, Bayer et al37 demonstrated that the 
prevalence of NODAT at 1 year increased with increas-
ing number of metabolic syndrome score 0: 0%, 1: 24%, 
2: 29%, 3: 31%, 4: 35%, 5: 74%, P = 0.001. Multivariate 
analysis incorporating the individual metabolic syndrome 
components as covariates demonstrated that of all the 
pre-transplant metabolic syndrome components, only low-
density lipoprotein was independently associated with the 
development of NODAT.
The precise role of the metabolic syndrome or metabolic 
syndrome component(s) in the development of NODAT 
remains to be defined. Nonetheless, the overlapping meta-
bolic risk factors for type 2 diabetes and cardiovascular 
disease (eg, obesity, hyperglycemia, dyslipidemia, hyperten-
sion) warrant early identification and aggressive management 
of individual risk factors.
Proteinuria
Early reports from a single-center study suggested an associa-
tion between proteinuria on day 5 after transplantation and 
the development of NODAT.38 However, these findings have 
been challenged because proteinuria on day 5 may just reflect 
the highly concentrated urine associated with hyperglycemia-
induced osmotic diuresis from the early posttransplant 
use of high dose corticosteroids or residual native kidney 
proteinuria. Furthermore, it has been shown that immediate 
posttransplant proteinuria generally resolves several weeks 
after transplantation.39 Nonetheless, in a subsequent single-
center retrospective study designed to evaluate the impact of 
early proteinuria (3 and 6 months after transplantation) and 
urinary albumin excretion (UAE) on NODAT, Roland et al40 
demonstrated that low-grade (,1 g/day) and very low-grade 
(,0.3 g/day) proteinuria were independent risk factors 
for NODAT (P = 0.0042 and P = 0.00025,   respectively). 
  Furthermore, there was a dose-dependent relationship across 
UAE categories with NODAT. NODAT-free survival was 
greater in patients with normoalbuminuria than in those 
with microalbuminuria, and greater in those with microalbu-
minuria than in those with macroalbuminuria (P = 0.0326). 
The authors also demonstrated that pulse pressure was an 
independent risk factor for NODAT, suggesting that early 
low-grade proteinuria and pulse pressure may be markers of 
the metabolic syndrome or vascular damage or both.
Hypomagnesemia
In the general population, not only has hypomagnesemia 
been shown to be associated with type 2 diabetes, but 
Table 2 Drug-induced NODAT: potential pathogenic mechanism(s)
Immunosuppressive  
agent
Pathogenic  
mechanism(s)
Comments
Corticosteroids •   ↓ Peripheral insulin  
sensitivity
•   inhibit pancreatic 
insulin production  
and secretion
•   ↑ Hepatic 
gluconeogenesis
•   Promote protein  
degradation to free  
amino acids in  
muscle, lipolysis
• Dose-dependent
•   impact of complete  
withdrawal of 
chronic low-dose 
steroids unclear
•   Potential ↓ NODAT  
risk in steroid-free  
regimens
Cyclosporine •   ↓ insulin secretion 
(CsA , Tac)
• ↓ insulin synthesis
• ↓ β-cell density
• Dose-dependent,
•   Diabetogenic effect ↑ 
with ↑ steroid dose*
Tacrolimus •   ↓ insulin secretion  
(Tac . CsA)
• ↓ insulin synthesis
• Dose-dependent,
•   Diabetogenic effect ↑ 
with ↑ steroid dose*
Sirolimus •   ↑ Peripheral insulin 
resistance
•   impair pancreatic 
β-cell response
•   ↑ Diabetogenicity 
when use with CNis
Note: *Demonstrated in some but not all studies.
Abbreviation: CNi, calcineurin inhibitors. 
Obesity
Similar to the general population, obesity has been shown 
to be associated with the development of NODAT in most 
studies.34 Analysis of the USRDS database revealed that 
obesity, defined as a BMI of $30 kg/m2 is one of the 
strongest risk factors for NODAT (Relative risk (RR) of 
1.73, P , 0.0001). Although some studies failed to demon-
strate an association between obesity and the development 
of NODAT, obesity and its associated peripheral insulin 
resistance state is a known risk factor for type 2 diabetes. 
The mechanism whereby obesity induces insulin resistance 
is poorly understood. Nonetheless, the pattern of body fat 
distribution has been suggested to play a contributory role. 
Studies in healthy women showed that upper body or male-
type obesity has a much greater association with insulin 
resistance and impaired glucose tolerance than lower body 
or female-type obesity.35 Similar studies in the transplant 
settings are lacking. It is speculated that intra-abdominal fat 
or waist-to-hip ratio may be more important risk factors for 
NODAT than total body weight or BMI.1
Hypertriglyceridemia/hypertension
Early retrospective studies suggested that the greater the 
number of the metabolic syndrome components, the greater 
the risk for the development of NODAT.36 In a recent Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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numerous studies have also reported an inverse   relationship 
between glycemic control and serum Mg levels.41 Similar 
to the nontransplant settings, hypomagnesemia has also 
been shown to be an independent predictor of NODAT in 
recipients of renal and liver transplants. In a single-cen-
ter retrospective analysis consisting of 254 renal transplant 
recipients, Van Laecke et al42 demonstrated that hypomag-
nesemia during the first-month posttransplantation was 
associated with the development of NODAT, independent 
of the immunosuppressive regimen used. While the associa-
tion between the use of CNIs was strongly related to hypo-
magnesemia, NODAT disappeared after adjustment for Mg 
levels suggesting that the diabetogenic effect of CNIs is at 
least in part related to hypomagnesemia.   Conversely, the 
use of mTOR inhibitors appeared to be a risk factor for 
NODAT after adjustment for Mg levels. The same group 
of authors subsequently demonstrated that both pretrans-
plant hypomagenesemia and hypomagnesemia in the first-
month posttransplantation were independent predictors of 
NODAT in recipients of liver transplants.43 Whether Mg 
supplementation and correction of Mg deficiency reduce 
the incidence of insulin resistance or NODAT remains to 
be studied.
Potentially modifiable risk factors
impaired glucose tolerance before transplantation
Abnormal glucose metabolism has been reported to be a 
risk factor for the development of NODAT in some but 
not all studies. In a study consisting of 490 recipients of 
kidney   transplants, Cosio et al44 demonstrated that higher 
pretransplant glucose is a risk factor for NODAT at one year. 
Using patients with pretransplant FPG levels between 90 and 
100 as the reference group, patients with plasma   glucose 
,90 mg/dL have lower risk of NODAT (OR = 0.46, P = 0.01). 
In contrast, the risk of NODAT increases as the   pretransplant 
FPG levels increases (FPG = 101–109, OR = 1.5; and 
FPG = 110–125, OR = 7.6, P , 0.0001). Among patients 
with IFG   pretransplant, 70% had hyperglycemia at one year 
(IFG 43% and NODAT 27%).
HCv-associated NODAT
The association between HCV infection and IFG, or 
the development of overt type 2 diabetes mellitus in the 
general population, has long been suggested. Potential 
mechanisms for the diabetogenic effect of HCV infec-
tion include insulin resistance; decreased hepatic glucose 
uptake and   glycogenesis; and direct cytopathic effect of the 
virus on pancreatic β cells.45 Similar to the non-transplant 
  settings, the link between hepatitis C and the   development 
of NODAT has also been recognized in solid organ trans-
plant recipients. The pathogenesis of HCV-associated 
NODAT, however, remains poorly understood. Clinical 
studies in OLT recipients have implicated insulin resistance 
associated with active HCV infection as a predominant 
pathogenic mechanism. Independent investigators have 
shown a temporal relationship between recurrent allograft 
hepatitis and increasing viral loads and the development 
of NODAT.4,45 Furthermore, patients who responded to 
antiviral therapy were observed to have improvement 
in glycemic control.4,46,47 In a small cohort of 17 non-
diabetic HCV-positive and 33 non-diabetic HCV-negative 
OLT recipients, Baid and colleagues4 have shown that the 
presence of HCV infection was independently associated 
with a 62% increase in insulin resistance (P = 0.0005). It 
was suggested that the virus had a direct effect on insulin 
resistance as no difference in β cell function or hepatic 
insulin extraction between the HCV-positive and negative 
groups was observed.
In a small study consisting of 16 renal transplant candi-
dates with sustained virologic response to interferon treat-
ment given in the pre-transplant period, none developed 
NODAT at a mean follow-up of 22.5 months (range, 2 to 
88 months).48 It is conceivable that successful pre-transplant 
treatment of hepatitis C could potentially reduce the incidence 
of NODAT after kidney transplantation.
Cytomegalovirus-associated NODAT
The link between cytomegalovirus (CMV) infection and 
the development of NODAT was first reported in 1985 in 
a renal transplant recipient.49 Limited studies suggested 
that both asymptomatic CMV infection and CMV dis-
ease are independent risk factors for the development of 
NODAT. In a study consisting of 160 consecutive non-
diabetic renal transplant recipients who were prospectively 
monitored for CMV infection during the first three months 
after   transplantation, Hjelmesaeth and colleagues50 found 
that asymptomatic CMV infection was associated with a 
four-fold increased risk of new-onset diabetes (adjusted 
RR = 4.00; P = 0.025). Patients with active CMV infection 
had a significantly lower median insulin release compared to 
their CMV negative counterparts, suggesting that impaired 
pancreatic β cell insulin release may be involved in the 
pathogenic mechanism of CMV-associated NODAT. It is 
speculated that CMV-induced release of proinflammatory 
cytokines may lead to apoptosis and functional disturbances 
of pancreatic β-cells.51Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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Impact of NODAT on patient  
and allograft outcomes
Clinical studies evaluating the impact of NODAT on patient 
and allograft outcomes after solid organ transplantation 
have yielded variable results. Nonetheless, there has been 
ample literature suggesting that kidney transplant recipients 
who developed NODAT are at a two- to three-fold increased 
risk of fatal and nonfatal cardiovascular disease events as 
compared with nondiabetic patients.52,53 The development of 
NODAT has also been shown to be associated with an adverse 
impact on patient survival and an increased risk of graft 
rejection and graft loss, as well as an increased incidence of 
infectious complications. In a study consisting of 173 renal 
transplant recipients, 1-year patient survival rates in those 
with, versus those without NODAT were 83% versus 98%, 
respectively (P , 0.01).54 Data from the United Renal Data 
System consisting of over 11,000 Medicare beneficiaries 
who received primary kidney transplants between 1996 and 
2000 demonstrated that compared to “no diabetes”, NODAT 
was associated with a 63% increased risk of graft failure 
(P , 0.0001), a 46% increased risk of death-censored graft 
failure (P , 0.0001) and an 87% increased risk of mortality 
(P , 0.0001).10
In contrast to earlier reports, a retrospective analysis of 
the UNOS/OPTN database (involving patients transplanted 
between 2004–2007) failed to demonstrate the negative 
impact of NODAT on transplant survival or CV mortality 
during a median follow-up of 548 days. The study consisted 
of .37,000 renal transplant recipients with a functioning 
transplant for at least 1 year. Risk stratification according to 
diabetes status (pre-transplant diabetes, NODAT) and acute 
rejection (AR) at 1 year demonstrated that pre-transplant 
diabetes is the major predictor of all-cause and cardiovas-
cular mortality, whereas acute rejection during the first year 
is the major predictor of death-censored transplant failure. 
In contrast, NODAT alone was not associated with any 
adverse outcomes specified in the study.55 Nonetheless, 
the study results were considered inconclusive given the 
wide confidence intervals and relatively short duration of 
follow-up.
Detection and management  
of diabetes mellitus in recipients  
of solid organ transplants
Pre-transplant baseline evaluation
The 2004 updated International Consensus Guidelines on 
New-onset Diabetes after Transplantation suggest that a 
  pre-transplant baseline evaluation should include a complete 
medical and family history, including documentation of glucose 
history.2 FPG should be tested at regular intervals and a 2-hour 
oral glucose tolerance test (OGTT) be performed in those with 
normal FPG. It has been suggested that the OGTT diagnostic 
criteria may be more sensitive in identifying patients with IGT 
than those set for FPG.1 Patients with evidence of IGT or abnor-
mal OGTT before transplantation should be counseled on life-
style modifications including weight control, diet, and exercise. 
The goals for the life-style modification involved achieving and 
maintaining a weight reduction of at least 7 percent of initial 
body weight through a healthy low-calorie, low-fat diet and at 
least 150 minutes of physical activity per week.
Pre-transplant treatment of HCV-infected renal transplant 
candidates should be considered. Selection of an immunosup-
pressive regimen should be tailored to each individual patient, 
weighing the risk of developing diabetes after transplantation 
against the risk of acute rejection. Suggested pretransplant 
baseline evaluation of potential transplant candidates is 
shown in Figure 2.
early detection of NODAT  
after transplantation
Studies investigating the best predictive tools for identifying 
patients at risk for developing NODAT early after transplan-
tation are currently lacking. While FPG is readily available, 
in clinical practice it may be normal in kidney transplant 
recipients with abnormal glucose homeostasis. It has been 
suggested that transplant patients have an atypical form of 
insulin resistance and their plasma glucose often peaks before 
lunch. Hence, the use of FPG alone may preclude the accu-
rate diagnosis of NODAT. Kuypers et al38 demonstrated that 
a normal (versus diabetic) OGTT on day 5 was associated 
Figure 2 Suggested pretransplant baseline evaluation of potential transplant candidates.
Note: *2003 international Consensus Guidelines.
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with a significantly reduced risk for NODAT (odds ratio 
0.03, P = 0.0002). However, it is noteworthy that while acute 
rejection has been suggested to increase the risk for NODAT, 
it usually does not occur before day 5. Obtaining OGTT 
and FPG at day 5, therefore, may fail to detect the subset of 
patients with higher risk of   developing NODAT. Hence, it 
has been suggested that performing OGTT at 10–12 weeks 
posttransplantation might be useful as an alternative or 
supplementary test to day 5 OGTT.56
The routine recommendation of performing an OGTT soon 
after transplantation needs further investigation.   Suggested 
pretransplant baseline evaluation and posttransplant screen-
ing for NODAT is shown in Figure 2.
Management of established NODAT
The management of NODAT should follow the conven-
tional approach for patients with type 2 diabetes mellitus 
as recommended by many clinical guidelines established 
by well-recognized organizations including the American 
Diabetes Association (ADA).
Similar to the nontransplant settings, a target hemo-
globin A1C level ,6.5% is recommended. Fasting plasma 
glucose should be below 100 mg/dL (6.11 mmol/L), and 
a 2-hour postprandial plasma glucose should be below 
140 mg/dL (7.77 mmol/L).57 Nonetheless, it should be noted 
that the Action to Control Cardiovascular Risk in Diabetes 
(ACCORD) trial was discontinued prematurely because 
of a statistically significant increase in all-cause mortal-
ity in the intensive- compared with the standard-glycemic 
treatment groups.58 At 1 year, stable median A1C levels of 
6.4% and 7.5% were achieved in the intensive-therapy and 
standard groups, respectively. The intensive-therapy group 
had a relative increase in mortality of 22% and an absolute 
increase of 1.0% during a follow-up period of 3.5 years. 
Death from cardiovascular causes was similar between the 
two treatment groups. It is also notable that hypoglycemia 
requiring assistance and weight gain of more than 10 kg was 
more frequent in the intensive-therapy group (P , 0.001). 
Long-term follow-up of the ACCORD study demonstrated 
that intensive therapy failed to reduce the risk of advanced 
measures of microvascular outcomes but delayed the onset 
of micro- and macro-albuminuria and some measures of 
ocular complications and peripheral neuropathy, which 
persisted over the 5 year study period despite the transition 
from intensive to conventional treatment of glycemia after 
3.7 years.59
Studies similar to that of the ACCORD study in recipients 
of solid organ transplantation are lacking. Nonetheless, the 
determination of hemoglobin A1C target levels for solid 
organ transplant recipients should be individualized based 
on hypoglycemia risks.
Modifiable risk factor management  
strategy
Dietary modification and physical activity
The Diabetes Prevention Program has demonstrated that a 
structured diet and physical activity program that achieves 
and maintains modest weight loss for overweight adults 
with IGT can significantly reduce the development of 
  diabetes. Defining realistic goals such as a target weight 
loss of 5%–10% of total body weight, and a patient-centered 
approach to education, may be invaluable in achieving 
success. Suggested non-insulin management of NODAT is 
shown in Table 3.
Modification of immunosuppression
Modification of immunosuppression should be considered 
in high-risk patients. Corticosteroid dose reduction has 
been shown to significantly improve glucose tolerance 
during the first year after transplantation.10 However, any 
dose reduction should be weighed against the risk of acute 
rejection. Steroid-sparing regimens or steroid avoidance 
protocols should be tailored to each individual patient. Tac 
to CSA conversion therapy in patients who fail to achieve 
target glycemic control or in those with difficult to control 
diabetes has yielded variable results. The use of CNI and 
mTOR inhibitor combination therapy should probably be 
avoided.
Renin-angiotensin inhibition
A meta-analysis of 10 randomized controlled trials to assess 
the effects of renin angiotensin inhibition [five with angio-
tensin-converting enzyme inhibitors (ACEIs) and five with 
angiotensin receptor blockers (ARBs)] on the incidence of 
new cases of type 2 diabetes mellitus in patients with arte-
rial hypertension and congestive heart failure demonstrated 
that renin-angiotensin inhibition with either ACEIs or ARBs 
consistently and significantly reduced the incidence of type 
2 diabetes mellitus compared with placebo, beta-blockers/
diuretics or amlodipine.60 This finding has not yet been 
validated in either transplant recipients or prospective trials 
in the general population.61 Similarly, data regarding direct 
renin inhibition on NODAT are lacking. Nonetheless, ACEI 
and ARB are widely used due to their well-established anti-
proteinuric, cardioprotective, and blood pressure lowering 
effects.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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Pharmacological management
When lifestyle modification fails to achieve adequate glyce-
mic control, medical intervention is recommended. Orally 
administered agents can be used either alone or in combination 
with other oral agents or insulin. The choice of pharmacologic 
therapy is based on the potential advantages and disadvantages 
associated with the different classes of oral agents. Table 3 sum-
marizes the mechanisms of action and potential advantages and 
disadvantages of different classes of oral agents.
It is noteworthy that the results of the Dialysis   Outcomes and 
Practice Patterns Study (DOPPS) demonstrated that in long-term 
hemodialysis patients, rosiglitazone was associated with a sig-
nificantly higher all-cause (hazard ratio 1.59) and   cardiovascular 
mortality and a 3.5 fold increase of hospitalizations due to 
myocardial infarction.62 In contrast to the DOPPS study results, 
in an analysis of the national cohort study consisting of more 
than 5,000 dialysis patients with type 2   diabetes, Brunelli et al63 
observed a lower incidence of all-cause mortality in patients 
not on insulin versus insulin requiring diabetic patients. Similar 
studies in the transplant settings are lacking. Nonetheless, great 
caution should be exercised when rosiglitazone is used in the 
setting of kidney transplantation because all kidney transplant 
recipients should be regarded as having at least stage II-IV 
chronic kidney disease. It should be noted that rosiglitazone 
has been suspended in Europe since 2010.
Incretin-based therapy appears to provide an attractive 
treatment option for patients with NODAT owing to its 
favorable effect on weight reduction/weight neutrality. 
Data on its safety and efficacy in renal transplant recipients 
are currently lacking. A randomized, placebo-controlled, 
double-blind, prospective trial to evaluate the safety and 
efficacy of vildagliptin in patients with NODAT is currently 
underway.64 Caution should be exercised when these agents 
are used in the transplant setting, particularly with regards 
to drug-to-drug interactions. Vildagliptin should be avoided 
in patients with hepatic impairment and stage IV-V chronic 
kidney disease and the dose of sitagliptin should be adjusted 
for renal insufficiency.65
Finally, drug to drug interactions should be carefully con-
sidered. Interested readers are referred to references.66–69
Summary
NODAT is a common complication after solid organ trans-
plantation and has variably been reported to have an adverse 
impact on patient and allograft outcomes. Risk stratification 
and intervention to minimize risk should be an integral part of 
the management of transplant recipients. Clinicians must be 
familiar with the patients’ immune history prior to manipu-
lating their immunosuppressive therapies in an attempt to 
ameliorate NODAT risk. When lifestyle modification fails 
Table 3 Non-insulin drug therapy for NODAT
Agents Action Adverse effects/comments
INSULIN SENSITIZERS
(eg, Metformin, Butoformin, Phenformin) ↓ hepatic glucose production,  
↑ glucose uptake by skeletal muscle
•   Diarrhea, dyspepsia, lactic acidosis w/renal  
insufficiency
• No weight gain, no hypoglycemia
INSULIN SECRETAGOGS
Sulfonylureas (SUs)  
(eg, Glipizide, Glyburide, Glimepiride)
Meglitinides 
(eg, Repaglinide, Nateglinide)
↑ pancreatic insulin secretion SUs: weight gain, edema, hypoglycemia (esp. in renal  
insufficiency and elderly)
Meglitinides: weight gain, hypoglycemia (lower risk 
than SUs)
Rapid onset and offset, hepatically excreted  
(use w/renal insufficiency)
OTHERS W/DIFFERENT ACTIONS
Thiazolidinedione derivatives (TZD)  
[eg, Pioglitazone, Rosiglitazone  
(use with caution, see text)]
Bind to peroxisome proliferator-activated  
receptors (PPARs) and stimulate insulin  
sensitive genes
•   weight gain, peripheral edema (esp. w/insulin),  
anemia, pulmonary edema, CHF, fractures
•   Slow onset of action, no hypoglycemia, no reliance on 
renal excretion, contraindicated in class iii-iv CHF or 
hepatic impairment
Glucagon-like peptide-1 analogs  
(eg, exenatide, Liraglutide)
↑ pancreatic insulin secretion either favorable or neutral effect on weight  
gain (delays gastric emptying, ↑ satiety)
Dipeptidyl peptidase 4 inhibitors  
(eg, Sitagliptin, Saxagliptin)
↑ endogenous incretins •   Avoid vildagliptin in hepatic impairment and stage iv-v  
CKD, dose should be adjusted for renal  
insufficiency
• watch for immunosuppresive drug interaction
•   weight neutral, no hypoglycemia, ? β cell preservationDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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to achieve adequate glycemic control, medical intervention 
is often necessary.
The routine care of patients with NODAT should include 
an evaluation of hemoglobin A1C level every three months 
and regular screening for diabetic complications. It should be 
noted that hemoglobin A1C cannot be   accurately interpreted 
within the first three months post transplantation due to 
  various factors including possible blood   transfusions in the 
early posttransplant period and the presence of anemia or 
impaired allograft function. Blood transfusions may render 
the test invalid until new hemoglobin is formed and the 
presence of anemia and   kidney impairment can directly 
interfere with the A1C assay. An artifactual reduction in A1C 
level has been reported in islet cell transplant recipients taking 
  dapsone for Pneumocystis carinii (P . jiroveci) prophylaxis. 
The cause is yet unknown, but a reduction in red blood cell 
lifespan and/or hemolysis has been implicated.70
Fasting lipid profile should be measured annually. In trans-
plant recipients with multiple CVD risk factors, more frequent 
monitoring of lipid profile should be performed at the discretion 
of the clinicians. Statins or the HMG-CoA reductase inhibi-
tors are the most widely used lipid lowering agents in both the 
nontransplant and transplant settings. Table 4 summarizes sug-
gested guidelines for the management of NODAT.71,72
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